Research Papers:
Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer
Metrics: PDF 2038 views | HTML 2676 views | ?
Abstract
Giuseppe S. Sica1,2, Cristina Fiorani1, Carmine Stolfi1, Giovanni Monteleone1, Eleonora Candi1, Ivano Amelio3, Valeria Catani1, Simone Sibio1, Andrea Divizia1, Giorgia Tema1, Edoardo Iaculli1, Achille L. Gaspari1
1Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
2European Society Degenerative Disease (ESDD). www.esdd.it
3Medical Research Council, Toxicology Unit, Leicester, UK
Correspondence to:
Giuseppe S. Sica, e-mail: [email protected]
Received: November 12, 2014 Accepted: November 27, 2014 Published: January 21, 2015
ABSTRACT
Recurrence of colorectal cancer (CRC) following a potentially curative resection is a challenging clinical problem. Matrix metalloproteinase-7 (MMP-7) is over-expressed by CRC cells and supposed to play a major role in CRC cell diffusion and metastasis. MMP-7 RNA expression was assessed by real-time PCR using specific primers in peritoneal washing fluid obtained during surgical procedure. After surgery, patients underwent a regular follow up for assessing recurrence. transcripts for MMP-7 were detected in 31/57 samples (54%). Patients were followed-up (range 20–48 months) for recurrence prevention. Recurrence was diagnosed in 6 out of 55 patients (11%) and two patients eventually died because of this. Notably, all the six patients who had relapsed were positive for MMP-7. Sensitivity and specificity of the test were 100% and 49% respectively. Data from patients have also been corroborated by computational approaches. Public available coloncarcinoma datasets have been employed to confirm MMP7 clinical impact on the disease. Interestingly, MMP-7 expression appeared correlated to Tgfb-1, and correlation of the two factors represented a poor prognostic factor. This study proposes positivity of MMP-7 in peritoneal cavity as a novel biomarker for predicting disease recurrence in patients with CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2830